|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
QUINOLONES MAY INCREASE THE EFFECT OF THEOPHYLLINE
|
THEOPHYLLINE PLASMA CLEARANCE IS INCREASED TO 7% BY FINASTERIDE
|
THEOPHYLLINE OVERDOSE SIDE EFFECTS ARE INCREASED BY THE CONCOMITANT USE OF THE DRUG
|
THEOPHYLLINE OVERDOSE SIDE EFFECTS ARE INCREASED BY THE CONCOMITANT USE OF THE DRUG
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
|
|
INCREASED INCIDENCE OF SIDE EFFECTS ON CO-ADMINISTRATION
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES DECREASE PLASMA CLEARANCE OF THE DRUG
|
XANTHINE DERIVATIVES SHOULD BE AVOIDED IN PATIENTS WITH ORGANOPHOSPHATE POISONING
|
INTERCONVERSION BETWEEN CAFFEINE AND THEOPHYLLINE HAS BEEN REPORTED IN PRETERM NEONATES ; THE CONCURRENT USE OF THESE DRUGS IS NOT RECOMMENDED
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
POTENTIAL FOR SEVERE AND FATAL REACTIONS INCLUDING CARDIAC ARREST, SEIZURES, RESPIRATORY FAILURE AND STATUS EPILEPTICUS ; CONCURRENT USE SHOULD BE AVOIDED OR SERUM LEVELS OF THEOPHYLLINE SHOULD BE MONITORED CAREFULLY
|
CO-ADMINISTRATION WITH BUPROPION MAY ALTER THE SEIZURE THRESHOLD
|
ADENOSINE ACTION IS INHIBITED BY THE DRUG
|
CO-ADMINISTRATION OF INTERFERON ALFA-2A WITH THEOPHYLLINE HAS BEEN REPORTED TO REDUCE THE THEOPHYLLINE CLEARANCE
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
THEOPHYLLIN POTENTIATES ITS METABOLISM , HENCE SERUM CONCENTRATION IS DECREASED
|
THEOPHYLLIN CLEARANCE IS INCREASED BY THE DRUG
|
THEOPHYLLIN CLEARANCE IS INCREASED BY THE DRUG
|
THEOPHYLLIN CLEARANCE IS INCREASED BY THE DRUG
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED PLASMA LEVELS WHILE THEOPHYLLINE INCREASES CARBAMAZEPINE METABOLISM & REDUCE ITS PLASMA LEVELS
|
METHYLXANTHINES ARE NON-SPECIFIC ADENOSINE RECEPTOR ANTAGONISTS & MAY INTERFERE WITH THE VASODILATATION
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|